FEMASYS INC

FEMYReported to SECin USCIK 0001339005Filings at SEC EDGAR

No score on this page, by design. Everything here is a fact from a public U.S. register: insider filings at the SEC (Form 4), lobbying filings under the Lobbying Disclosure Act, trades reported by members of Congress under the STOCK Act, and fund holdings in 13F filings. Our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.

This page is free to read, and it stops after 5 rows. Those are the 5 most recent Form 4 lines at this company, out of 20. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

The most recent filings

Most recent filing first: every line of every Form 4 at this company that passed our review, the same lines as on the register. Reported is the day the filing reached the SEC, usually within two business days of the trade. Amounts are in U.S. dollars, as the form states them.

5 of 20
Form 4 lines at FEMASYS INC, most recent filing first
Filed byTypeValueReportedFiled byValueTypeSharesReported
Eichenbaum Kenneth D.—Awardnothing paid880 sharesAug 11, 2026Eichenbaum Kenneth D.nothing paidAward · Aug 11Award880Aug 11, 2026
Uzialko Edward R—Awardnothing paid880 sharesAug 11, 2026Uzialko Edward Rnothing paidAward · Aug 11Award880Aug 11, 2026
Milnes Alistair—Awardnothing paid880 sharesAug 11, 2026Milnes Alistairnothing paidAward · Aug 11Award880Aug 11, 2026
Larsen Charles—Awardnothing paid880 sharesAug 11, 2026Larsen Charlesnothing paidAward · Aug 11Award880Aug 11, 2026
Mifek Jeffrey GeraldChief Clinical-Medical AffairsAward—3,125 sharesAug 11, 2026Mifek Jeffrey GeraldChief Clinical-Medical Affairs—Award · Aug 11Award3,125Aug 11, 2026

Lobbying

From the quarterly LD-2 filings at the U.S. Senate — a different register, and a different kind of fact.

This is not a trade and it is not scored. A lobbying filing says who lobbied for whom, on which issues, and for how much — it says nothing about the share price and nothing about this company’s insiders. The link between the client names in that register and FEMASYS INC is a reviewed rule of ours: an LD-2 names a client and carries no ticker, no CIK and no LEI.

Most recent quarterQ4 20241 report counted in that quarter
Reported that quarter$10,000 reported incomewhat the filings for that quarter state, in the words of the form
Client names1one client name in the register maps to this company

Every lobbying filing we hold for FEMY

Lobbying reported per quarter

reported amounts per quarter, latest version of each report

Reported income: what lobbying firms reported receiving from this company's clients, per quarter.

Before 2025, these bars cover only the lobbying relationships that were still active in 2025 or later. Engagements that ended earlier are not included, so those years may be higher than shown.

Reported income

Q1Q2Q3Q4
$0$50k$100k2024: $10k Q1, $40k Q2, $40k Q3, $10k Q42024